|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Surveys of transmitted HIV drug resistance in 7 geographic regions in China, 2008-2009 显示文摘 | Liao L Xing H Dong Y Qin G Ma Y Lu H Chen L Zhang L Osborne C Seguy N Wei D Sun F Yang J Ru- an Y Shao Y | 2012 | Clin Infect Dis2012，54，4： | 1 |
| 2 | Analysis of the pathologic response to primary chemotherapyin patients with locally ad- vanced breast cancer grouped according to estrogen receptor, progester- one receptor, and Her-2 status 显示文摘 | Fernandez - Morales LA Segui MA Andreu X | 2007 | Clin Breast Cancer2007，7，7： | 1 |
| 3 | Prognostic value of HER2/neu and p53 expression in node 2 positive breast cancer HER2/neu effect on adjuvant tamoxifen treatment 显示文摘 | Climent MA Segui MA Peiro G | 2001 | Breast2001，10，1： | 1 |
| 4 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel ,doxorubicin, cyclophosphamide (TAG) or 5-fluorouracil, doxorubicin, cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen显示文摘 | Martin M Lluch A Segui MA | 2006 | Ann Oncol2006，17，8： | 1 |
| 5 | Adjuvant docetaxel for high- risk,node-negative breast cancer 显示文摘 | Martin M Segui MA Anton A | 2010 | N Engl J Med2010，363，23： | 1 |
| 6 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel,doxorubicin,cyclophosphamide (TAC) or 5-fluorouracil,doxorubicin and cyclophosphamide (FAC):impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen显示文摘 | Martin M Lluch A Segui MA | 2006 | Ann Oncol2006，17，8： | 1 |
| 7 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel,doxorubicin,cyclophosphamide (TAC) or 5-fluorouracil,doxorubicin and cyclophosphamide (FAC):impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen显示文摘 | Martin M Lluch A Segui MA | 2006 | Ann Oncol2006，17，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员